ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 学会発表・講演等
  2. 口頭発表

Gene expression profiling identifies molecular targets to enhance the cytotoxicity of Auger electron radioimmunotherapy

https://repo.qst.go.jp/records/65779
https://repo.qst.go.jp/records/65779
62024880-598d-4a9a-bf58-59ee4ded05c2
Item type 会議発表用資料 / Presentation(1)
公開日 2015-10-14
タイトル
タイトル Gene expression profiling identifies molecular targets to enhance the cytotoxicity of Auger electron radioimmunotherapy
言語
言語 eng
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_c94f
資源タイプ conference object
アクセス権
アクセス権 metadata only access
アクセス権URI http://purl.org/coar/access_right/c_14cb
著者 Hasegawa, Sumitaka

× Hasegawa, Sumitaka

WEKO 647937

Hasegawa, Sumitaka

Search repository
Furukawa, Takako

× Furukawa, Takako

WEKO 647938

Furukawa, Takako

Search repository
Saga, Tsuneo

× Saga, Tsuneo

WEKO 647939

Saga, Tsuneo

Search repository
長谷川 純崇

× 長谷川 純崇

WEKO 647940

en 長谷川 純崇

Search repository
古川 高子

× 古川 高子

WEKO 647941

en 古川 高子

Search repository
佐賀 恒夫

× 佐賀 恒夫

WEKO 647942

en 佐賀 恒夫

Search repository
抄録
内容記述タイプ Abstract
内容記述 Auger electron (AE)-emitters such as I-125 and In-111 are highly cytotoxic when they decay in the nucleus because of their high local energy deposition. The use of antibody modified with nuclear localizing signal (NLS) has been proposed to achieve the efficient delivery of AE-emitters into tumor cell nucleus. [In-111]trastuzumab-NLS is a promising radiopharmaceutical in AE radioimmunotherapy for targeted killing of HER2-positive cancers. However, for further improvement of its therapeutic efficacy, better understanding of cellular response to [In-111]trastuzumab-NLS is required. We performed DNA microarray analysis in HER2-overexpressing human breast cancer SKBR3 cells treated with [In-111]trastuzumab-NLS and identified the modulation of NF-kB signaling activity as a molecular signature of [In-111]trastuzumab-NLS treatment. Thirty-eight of genes in NF-kB targets were transcriptionally altered by [In-111]trastuzumab-NLS treatment. Furthermore, bortezomib, a NF-kB pathway modulator drug, significantly enhanced the cytotoxicity of [In-111]trastuzumab-NLS in SKBR3 cells in comparison to monotherapy of [In-111]trastuzumab-NL
会議概要(会議名, 開催地, 会期, 主催者等)
内容記述タイプ Other
内容記述 第74回日本癌学会学術総会
発表年月日
日付 2015-10-10
日付タイプ Issued
戻る
0
views
See details
Views

Versions

Ver.1 2023-05-15 20:56:21.337924
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3